Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib open-label dose-escalation study of xentuzumab + abemaciclib ± endocrine therapy in advanced solid tumours and HR+ HER2- breast cancer
jRCT2080223555Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of xentuzumab and abemaciclib in Nonhematologic neoplasms, breast cancer and non-small cell lung cancer (NSCLC) (8 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Safety and tolerability and Dose-escalation and recommended phase II dose. Started Jun 2017; status: completed.
02
Drugs
xentuzumababemaciclib
03
Conditions
Nonhematologic neoplasmsbreast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223555.